Developer docs
API playgroundTry for free, no card

Search company profiles

MiRus

Full company profile

uuid00024mm

Namestring
MiRus
Legal namestring
MiRus, LLC
Websiteurl
mirusmed.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

MiRus, LLC is a privately-held medical device company headquartered in Marietta, Georgia, that designs and commercializes implants and procedural solutions built on a proprietary molybdenum-rhenium superalloy (MoRe) for the treatment of cardiovascular, orthopedic, and spinal disease. The company's core technology is a nickel-free Mo-47.5Re biomaterial — adapted from material science originally developed for NASA rocket engines — that delivers roughly 2.5x the yield strength (280 ksi vs ~115 ksi for titanium), superior fatigue resistance (350N max run-out load for a 4.0mm rod vs 150-200N for 5.5mm conventional rods), minimal recoil (<2% vs 6-9%), and lower metal ion release than titanium or cobalt-chromium alloys. This material platform, protected by global patent coverage, underwrites the company's product portfolio across three verticals: spine (EUROPA pedicle screw and posterior cervical systems, CYGNUS anterior cervical plate, 3DR interbody fusion, RIGEL, ANTARES, VITESSE), extremity (ATLAS foot and ankle plating, AURORA screws, IO Expandable Wedge Osteotomy), and structural heart (SIEGEL balloon-expandable TAVR with 8 French delivery — currently investigational in the STAR pivotal trial). The portfolio also includes GALILEO, a wireless intra-operative spine alignment monitoring system using disposable MEMS sensors.

The company operates a vertically-segmented go-to-market targeting hospitals and healthcare systems across spine, orthopedic, and cardiovascular surgery. Its commercial motion combines a direct enterprise field sales organization (led by CCO Mahesh Krishnan) with a US distributor network managed through a dedicated distributor portal (distributor.mirusmed.com). Revenue is generated through one-time hardware sales of proprietary implants and procedural kits to hospitals, with no public pricing disclosed. Clinical adoption is driven by medical conference presentations (NY Valves, TCT, NASS, AANS/CNS Spine Summit, AOFAS), peer-reviewed publications, and an in-house CME webinar series ("EXPECT MoRe"), and reinforced by KOL engagement at high-volume academic centers (Piedmont Heart Institute, Cedars Sinai, Stanford, Mayo Clinic, Hospital for Special Surgery, University of Illinois Chicago).

The business has scaled rapidly since founding, achieving over 250% growth in the two years prior to 2022 (Atlanta Business Chronicle 2022 Pacesetter Award) and accumulating FDA 510(k) clearances across each product vertical, plus an FDA Breakthrough Device Designation and CMS New Technology Add-on Payment (up to $80,548) for the EUROPA Posterior Cervical Fusion System. In May 2026, Boston Scientific invested $1.5 billion for approximately 34% equity, with an exclusive option to acquire the SIEGEL TAVR business for up to an additional $3 billion upon clinical and regulatory milestones, plus an option on mitral and tricuspid replacement valve assets — effectively validating the company as a strategic cardiovascular acquisition target and providing capital to drive the 1,025-patient STAR pivotal trial toward potential SIEGEL TAVR approval.

Short descriptiontext

MiRus designs and commercializes proprietary molybdenum-rhenium (MoRe) superalloy medical implants and procedural solutions for hospitals and healthcare systems, serving spine, extremity/foot-ankle, and structural heart (TAVR) surgery markets across the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMarietta, United States
HQ citystring
Marietta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthopedic medical devices, spinal implants, cardiovascular implants, biomaterial medical devices, structural heart devices
Industry4 codes
PRIMARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAL
Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Orthopedic and Cardiovascular Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Spine, Orthopedic, Structural Heart)
TypeHardware Sales
Description

MiRus generates revenue through the sale of proprietary medical implants and procedural solutions for spine, orthopedic/extremity, and structural heart diseases. Products include pedicle screw systems, interbody cages, plating systems, osteotomy devices, and the SIEGEL TAVR system (investigational, not yet approved). Revenue is one-time product-based with recurring purchasing by hospital/healthcare system customers.

mirusmed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1MoRe
Description

Proprietary molybdenum-rhenium superalloy used in MiRus implants, offering superior strength, ductility, durability, and biological safety compared to traditional implant materials like titanium and cobalt chromium.

mirusmed.com
+11 more records
Core offering1 text field

MiRus designs, manufactures, and commercializes medical implants and procedural solutions for spine, extremity/orthopedic, and structural heart applications, all built on its proprietary MoRe (Molybdenum-47.5 Rhenium) nickel-free superalloy. The integrated platform spans pre-operative planning (e.g., GALILEO), intra-operative implants (pedicle screws, interbody cages, cervical plates, foot/ankle plates, TAVR), and post-operative monitoring. The company sells these products to hospitals and healthcare systems in the United States through an enterprise field sales team and a distributor network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Zero rod fractures in 159 consecutive complex spine surgery patients at mean 22-month follow-up (vs ~9% rod fracture rate with conventional alloys)
+4 more records
Product and service12 records
1SIEGEL TAVR (Transcatheter Aortic Valve Replacement)
CategoryStructural Heart / Cardiovascular Implants
Description

First nickel-free balloon-expandable transcatheter aortic valve replacement system, targeting severe aortic stenosis. Designed for interventional cardiologists and cardiac surgeons performing TAVR procedures at hospital systems; the device enables a 50% smaller delivery sheath than current commercial TAVR systems.

2EUROPA Pedicle Screw System
CategorySpinal Implants
Description

Spinal fusion implant system using MoRe alloy for thoracolumbar pedicle screw fixation, targeting spine surgeons and hospitals performing spinal fusion and deformity correction procedures. The 4.5mm MoRe rod offers 350N max run-out load versus 150-200N for conventional 5.5mm rods.

3EUROPA Posterior Cervical Fusion (PCF) System
CategorySpinal Implants
Description

Posterior cervical fusion system for treatment of the cervical and upper thoracic spine using proprietary rhenium alloy. Aimed at spine surgeons at hospital systems, with FDA Breakthrough Designation and CMS NTAP reimbursement status.

4CYGNUS Anterior Cervical Plate System
CategorySpinal Implants
Description

Anterior cervical plate system using MoRe alloy, positioned as the world's lowest profile and smallest footprint anterior cervical plate. Targeted at spine surgeons performing anterior cervical discectomy and fusion (ACDF) procedures.

53DR Lateral Lumbar Interbody Fusion System
CategorySpinal Implants
Description

3D-printed titanium lateral lumbar interbody fusion cage with randomized lattice structure mimicking cancellous bone (elastic modulus 0.53 GPa) for superior bone apposition and ingrowth. Designed for spine surgeons performing lateral lumbar interbody fusion (LLIF) procedures.

6ATLAS Foot and Ankle Plating System
CategoryExtremity / Orthopedic Implants
Description

Foot and ankle plating system using MoRe alloy with 1.0mm thickness, the thinnest foot and ankle plate on the market. Targeted at orthopedic foot and ankle surgeons performing fracture fixation and reconstruction procedures.

7IO Expandable Wedge Osteotomy System
CategoryExtremity / Orthopedic Implants
Description

Expandable wedge osteotomy implant using MoRe alloy and MiRus's MoRe Expansion Engine technology, enabling surgeons to make controlled, incremental intraoperative adjustments during foot and ankle osteotomy procedures.

8GALILEO Spine Alignment Monitoring System
CategoryProcedural Solutions / Surgical Planning
Description

Wireless, real-time intraoperative spine alignment monitoring system using disposable miniaturized wireless MEMS sensors, providing dynamic measurement of intervertebral angles and overall spinal alignment with accuracy within +/- 3 degrees. Targeted at spine surgeons for pre-operative and intra-operative alignment verification.

9RIGEL Cervical Interbody System
CategorySpinal Implants
Description

Cervical interbody system including corpectomy and standalone anterior cervical options with flexible fixation choices. Targeted at spine surgeons performing cervical reconstruction and fusion procedures.

10ANTARES Standalone ALIF System
CategorySpinal Implants
Description

Standalone anterior lumbar interbody fusion (ALIF) system with multiple screw configuration options for maximal intraoperative fixation. Aimed at spine surgeons performing ALIF procedures at hospital systems.

11AURORA Foot and Ankle Screw System
CategoryExtremity / Orthopedic Implants
Description

Foot and ankle screw system using MoRe alloy, designed for orthopedic foot and ankle surgeons performing fracture fixation and reconstruction procedures.

12VITESSE Pedicle Screw Insertion System
CategoryProcedural Solutions / Surgical Instruments
Description

Pedicle screw insertion instrumentation system used to implant MiRus's pedicle screw-based spinal fusion products. Targeted at spine surgeons and hospital operating room staff.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOthersAnnounced on2026-04-08
Description

Piedmont Heart Institute served as the site for first patient enrollment and treatment in the STAR pivotal trial of the Siegel TAVR. Pradeep K. Yadav, MD (National Co-Principal Investigator) and Vinod H. Thourani, MD (Marcus Chairman of Cardiovascular Surgery and National Co-Chairman) performed the first procedures. Piedmont Heart Institute is the Marcus Valve Center and a key clinical trial site.

Strategic tierMinorTypeOthers
Description

Cedars Sinai Heart Institute participated as one of five US medical centers in the Siegel TAVR Early Feasibility Study (EFS). Raj R. Makkar, MD presented 30-day EFS results at the NY Valves meeting.

Strategic tierMinorTypeOthers
Description

Mayo Clinic participated as one of five US medical centers in the Siegel TAVR Early Feasibility Study (EFS).

Strategic tierMinorTypeOthers
Description

Stanford participated as one of five US medical centers in the Siegel TAVR Early Feasibility Study (EFS).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

TAVR market leader (SAPIEN platform, ~60% global share) and the most direct competitor for MiRus's SIEGEL TAVR system. Comparable on transcatheter aortic valve replacement technology, structural heart commercial model, and regulatory pathway.

TypeDirect peer
Description

Mid-cap orthopedic company with spine (Mesa, Firebird, CONSTRUX), extremity (foot/ankle and biologics), and procedural solution portfolios. Closest peer in scale and vertical scope to MiRus with similar breadth across cervical/lumbar/extremity.

TypeDirect peer
Description

Pure-play spine implant company with cervical (DT, Invictus), thoracolumbar, and interbody products directly competing with MiRus's EUROPA, CYGNUS, RIGEL, ANTARES, and 3DR. Comparable on growth-stage spine implant commercialization.

TypeBroad incumbent
Description

Large diversified medtech incumbent with spine (CD Horizon, Mazor robotics), structural heart (Evolut TAVR), and broad orthopedic portfolios. Competes with MiRus on both spine implants and the TAVR market SIEGEL targets, with a much broader product portfolio and established hospital relationships.

TypeDirect peer
Description

Pure-play spine and orthopedic implant company (now merged with NuVasive). Directly comparable as a spine-focused implant manufacturer with pedicle screw, interbody, and cervical plate product lines that compete head-to-head with MiRus's EUROPA, CYGNUS, 3DR, and IO systems across similar hospital customers.

TypeBroad incumbent
Description

Large diversified orthopedic medtech major with spine (acquired via Wright Medical/K2M) and extremity (foot/ankle from Wright Medical) portfolios that overlap with MiRus's spine (EUROPA, RIGEL, ANTARES) and extremity (ATLAS, AURORA, IO) franchises. Approached as a broad incumbent likely to evaluate MoRe alloy via M&A or competing material science.

TypeEmerging player
Description

Privately held 3D-printed spinal implant manufacturer with proprietary lattice/truss structure technology analogous to MiRus's 3DR system. Comparable as a niche 3D-printed spine technology peer pursuing structural bone-ingrowth advantages in similar cervical/thoracolumbar indications.

TypeBroad incumbent
Description

Now MiRus's largest shareholder (34% stake, May 2026, with exclusive $3B TAVR acquisition option). Comparable as a broad structural heart/TAVR incumbent (ACURATE neo) with overlapping cardiovascular ambitions, and a likely future acquirer of the TAVR business.

TypeDirect peer
Description

Spine-only implant company with cervical, thoracolumbar, interbody, and orthobiologics portfolios; now combined with Globus Medical. Direct overlap with MiRus's spine implant franchise in similar hospital channels.

TypeDirect peer
Description

Foot/ankle/upper extremity orthopedic implant specialist (now part of Stryker) directly comparable to MiRus's extremity franchise (ATLAS plating, AURORA screw, IO Expandable Wedge Osteotomy System) in similar podiatric/orthopedic foot and ankle surgeon customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MiRus

Orthopedic and Cardiovascular Medical Devicesmirusmed.com

MiRus designs and commercializes proprietary molybdenum-rhenium (MoRe) superalloy medical implants and procedural solutions for hospitals and healthcare systems, serving spine, extremity/foot-ankle, and structural heart (TAVR) surgery markets across the US.

What MiRus does

MiRus, LLC is a privately-held medical device company headquartered in Marietta, Georgia, that designs and commercializes implants and procedural solutions built on a proprietary molybdenum-rhenium superalloy (MoRe) for the treatment of cardiovascular, orthopedic, and spinal disease. The company's core technology is a nickel-free Mo-47.5Re biomaterial — adapted from material science originally developed for NASA rocket engines — that delivers roughly 2.5x the yield strength (280 ksi vs ~115 ksi for titanium), superior fatigue resistance (350N max run-out load for a 4.0mm rod vs 150-200N for 5.5mm conventional rods), minimal recoil (<2% vs 6-9%), and lower metal ion release than titanium or cobalt-chromium alloys. This material platform, protected by global patent coverage, underwrites the company's product portfolio across three verticals: spine (EUROPA pedicle screw and posterior cervical systems, CYGNUS anterior cervical plate, 3DR interbody fusion, RIGEL, ANTARES, VITESSE), extremity (ATLAS foot and ankle plating, AURORA screws, IO Expandable Wedge Osteotomy), and structural heart (SIEGEL balloon-expandable TAVR with 8 French delivery — currently investigational in the STAR pivotal trial). The portfolio also includes GALILEO, a wireless intra-operative spine alignment monitoring system using disposable MEMS sensors.

The company operates a vertically-segmented go-to-market targeting hospitals and healthcare systems across spine, orthopedic, and cardiovascular surgery. Its commercial motion combines a direct enterprise field sales organization (led by CCO Mahesh Krishnan) with a US distributor network managed through a dedicated distributor portal (distributor.mirusmed.com). Revenue is generated through one-time hardware sales of proprietary implants and procedural kits to hospitals, with no public pricing disclosed. Clinical adoption is driven by medical conference presentations (NY Valves, TCT, NASS, AANS/CNS Spine Summit, AOFAS), peer-reviewed publications, and an in-house CME webinar series ("EXPECT MoRe"), and reinforced by KOL engagement at high-volume academic centers (Piedmont Heart Institute, Cedars Sinai, Stanford, Mayo Clinic, Hospital for Special Surgery, University of Illinois Chicago).

The business has scaled rapidly since founding, achieving over 250% growth in the two years prior to 2022 (Atlanta Business Chronicle 2022 Pacesetter Award) and accumulating FDA 510(k) clearances across each product vertical, plus an FDA Breakthrough Device Designation and CMS New Technology Add-on Payment (up to $80,548) for the EUROPA Posterior Cervical Fusion System. In May 2026, Boston Scientific invested $1.5 billion for approximately 34% equity, with an exclusive option to acquire the SIEGEL TAVR business for up to an additional $3 billion upon clinical and regulatory milestones, plus an option on mitral and tricuspid replacement valve assets — effectively validating the company as a strategic cardiovascular acquisition target and providing capital to drive the 1,025-patient STAR pivotal trial toward potential SIEGEL TAVR approval.

MiRus firmographics

Firmographics
Name
MiRus
Legal name
MiRus, LLC
Website
https://mirusmed.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
MiRus designs and commercializes proprietary molybdenum-rhenium (MoRe) superalloy medical implants and procedural solutions for hospitals and healthcare systems, serving spine, extremity/foot-ankle, and structural heart (TAVR) surgery markets across the US.
Ownership category
akta.pro rank

MiRus industry classification

Industry
Product category
Orthopedic and Cardiovascular Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAL
Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Orthopedic medical devices
  • Spinal implants
  • Cardiovascular implants
  • Biomaterial medical devices
  • Structural heart devices

Where MiRus is headquartered

Location

Headquarters

HQ city
Marietta
HQ country
United States
HQ region
North America

Offices2 records

Markets served

MiRus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

  1. Medical Device Sales (Spine, Orthopedic, Structural Heart): MiRus generates revenue through the sale of proprietary medical implants and procedural solutions for spine, orthopedic/extremity, and structural heart diseases. Products include pedicle screw systems, interbody cages, plating systems, osteotomy devices, and the SIEGEL TAVR system (investigational, not yet approved). Revenue is one-time product-based with recurring purchasing by hospital/healthcare system customers.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

MiRus product offering

Product offering

Core offering

MiRus designs, manufactures, and commercializes medical implants and procedural solutions for spine, extremity/orthopedic, and structural heart applications, all built on its proprietary MoRe (Molybdenum-47.5 Rhenium) nickel-free superalloy. The integrated platform spans pre-operative planning (e.g., GALILEO), intra-operative implants (pedicle screws, interbody cages, cervical plates, foot/ankle plates, TAVR), and post-operative monitoring. The company sells these products to hospitals and healthcare systems in the United States through an enterprise field sales team and a distributor network.

Differentiator

Problem solved

Functional benefit

Brands

  • MoRe: Proprietary molybdenum-rhenium superalloy used in MiRus implants, offering superior strength, ductility, durability, and biological safety compared to traditional implant materials like titanium and cobalt chromium.
  • Siegel TAVR
  • EUROPA
  • CYGNUS
  • ATLAS
  • 3DR
  • IO
  • GALILEO
  • RIGEL
  • ANTARES
  • AURORA
  • VITESSE

Products and services

  • SIEGEL TAVR (Transcatheter Aortic Valve Replacement) First nickel-free balloon-expandable transcatheter aortic valve replacement system, targeting severe aortic stenosis. Designed for interventional cardiologists and cardiac surgeons performing TAVR procedures at hospital systems; the device enables a 50% smaller delivery sheath than current commercial TAVR systems.
  • EUROPA Pedicle Screw System Spinal fusion implant system using MoRe alloy for thoracolumbar pedicle screw fixation, targeting spine surgeons and hospitals performing spinal fusion and deformity correction procedures. The 4.5mm MoRe rod offers 350N max run-out load versus 150-200N for conventional 5.5mm rods.
  • EUROPA Posterior Cervical Fusion (PCF) System Posterior cervical fusion system for treatment of the cervical and upper thoracic spine using proprietary rhenium alloy. Aimed at spine surgeons at hospital systems, with FDA Breakthrough Designation and CMS NTAP reimbursement status.
  • CYGNUS Anterior Cervical Plate System Anterior cervical plate system using MoRe alloy, positioned as the world's lowest profile and smallest footprint anterior cervical plate. Targeted at spine surgeons performing anterior cervical discectomy and fusion (ACDF) procedures.
  • 3DR Lateral Lumbar Interbody Fusion System 3D-printed titanium lateral lumbar interbody fusion cage with randomized lattice structure mimicking cancellous bone (elastic modulus 0.53 GPa) for superior bone apposition and ingrowth. Designed for spine surgeons performing lateral lumbar interbody fusion (LLIF) procedures.
  • ATLAS Foot and Ankle Plating System Foot and ankle plating system using MoRe alloy with 1.0mm thickness, the thinnest foot and ankle plate on the market. Targeted at orthopedic foot and ankle surgeons performing fracture fixation and reconstruction procedures.
  • IO Expandable Wedge Osteotomy System Expandable wedge osteotomy implant using MoRe alloy and MiRus's MoRe Expansion Engine technology, enabling surgeons to make controlled, incremental intraoperative adjustments during foot and ankle osteotomy procedures.
  • GALILEO Spine Alignment Monitoring System Wireless, real-time intraoperative spine alignment monitoring system using disposable miniaturized wireless MEMS sensors, providing dynamic measurement of intervertebral angles and overall spinal alignment with accuracy within +/- 3 degrees. Targeted at spine surgeons for pre-operative and intra-operative alignment verification.
  • RIGEL Cervical Interbody System Cervical interbody system including corpectomy and standalone anterior cervical options with flexible fixation choices. Targeted at spine surgeons performing cervical reconstruction and fusion procedures.
  • ANTARES Standalone ALIF System Standalone anterior lumbar interbody fusion (ALIF) system with multiple screw configuration options for maximal intraoperative fixation. Aimed at spine surgeons performing ALIF procedures at hospital systems.
  • AURORA Foot and Ankle Screw System Foot and ankle screw system using MoRe alloy, designed for orthopedic foot and ankle surgeons performing fracture fixation and reconstruction procedures.
  • VITESSE Pedicle Screw Insertion System Pedicle screw insertion instrumentation system used to implant MiRus's pedicle screw-based spinal fusion products. Targeted at spine surgeons and hospital operating room staff.

Quantifiable outcome

  • Zero rod fractures in 159 consecutive complex spine surgery patients at mean 22-month follow-up (vs ~9% rod fracture rate with conventional alloys)
  • +4 more outcomes

Companies that use MiRus

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles4 records

MiRus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MiRus partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Piedmont Heart InstitutecoreOthers · 8 April 2026Piedmont Heart Institute served as the site for first patient enrollment and treatment in the STAR pivotal trial of the Siegel TAVR. Pradeep K. Yadav, MD (National Co-Principal Investigator) and Vinod H. Thourani, MD (Marcus Chairman of Cardiovascular Surgery and National Co-Chairman) performed the first procedures. Piedmont Heart Institute is the Marcus Valve Center and a key clinical trial site.
  • Cedars Sinai Heart InstituteminorOthersCedars Sinai Heart Institute participated as one of five US medical centers in the Siegel TAVR Early Feasibility Study (EFS). Raj R. Makkar, MD presented 30-day EFS results at the NY Valves meeting.
  • Mayo ClinicminorOthersMayo Clinic participated as one of five US medical centers in the Siegel TAVR Early Feasibility Study (EFS).
  • StanfordminorOthersStanford participated as one of five US medical centers in the Siegel TAVR Early Feasibility Study (EFS).

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

MiRus competitors and assessment

Company assessment

Direct peers

  • Edwards Lifesciences: TAVR market leader (SAPIEN platform, ~60% global share) and the most direct competitor for MiRus's SIEGEL TAVR system. Comparable on transcatheter aortic valve replacement technology, structural heart commercial model, and regulatory pathway.
  • Orthofix Medical: Mid-cap orthopedic company with spine (Mesa, Firebird, CONSTRUX), extremity (foot/ankle and biologics), and procedural solution portfolios. Closest peer in scale and vertical scope to MiRus with similar breadth across cervical/lumbar/extremity.
  • Alphatec Holdings: Pure-play spine implant company with cervical (DT, Invictus), thoracolumbar, and interbody products directly competing with MiRus's EUROPA, CYGNUS, RIGEL, ANTARES, and 3DR. Comparable on growth-stage spine implant commercialization.
  • Globus Medical: Pure-play spine and orthopedic implant company (now merged with NuVasive). Directly comparable as a spine-focused implant manufacturer with pedicle screw, interbody, and cervical plate product lines that compete head-to-head with MiRus's EUROPA, CYGNUS, 3DR, and IO systems across similar hospital customers.
  • SeaSpine (now Globus Medical): Spine-only implant company with cervical, thoracolumbar, interbody, and orthobiologics portfolios; now combined with Globus Medical. Direct overlap with MiRus's spine implant franchise in similar hospital channels.
  • Wright Medical (Stryker Trauma & Extremities): Foot/ankle/upper extremity orthopedic implant specialist (now part of Stryker) directly comparable to MiRus's extremity franchise (ATLAS plating, AURORA screw, IO Expandable Wedge Osteotomy System) in similar podiatric/orthopedic foot and ankle surgeon customers.

Broad incumbents

  • Medtronic: Large diversified medtech incumbent with spine (CD Horizon, Mazor robotics), structural heart (Evolut TAVR), and broad orthopedic portfolios. Competes with MiRus on both spine implants and the TAVR market SIEGEL targets, with a much broader product portfolio and established hospital relationships.
  • Stryker: Large diversified orthopedic medtech major with spine (acquired via Wright Medical/K2M) and extremity (foot/ankle from Wright Medical) portfolios that overlap with MiRus's spine (EUROPA, RIGEL, ANTARES) and extremity (ATLAS, AURORA, IO) franchises. Approached as a broad incumbent likely to evaluate MoRe alloy via M&A or competing material science.
  • Boston Scientific: Now MiRus's largest shareholder (34% stake, May 2026, with exclusive $3B TAVR acquisition option). Comparable as a broad structural heart/TAVR incumbent (ACURATE neo) with overlapping cardiovascular ambitions, and a likely future acquirer of the TAVR business.

Emerging players

  • 4WEB Medical: Privately held 3D-printed spinal implant manufacturer with proprietary lattice/truss structure technology analogous to MiRus's 3DR system. Comparable as a niche 3D-printed spine technology peer pursuing structural bone-ingrowth advantages in similar cervical/thoracolumbar indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

MiRus social profiles

Digital presence

MiRus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MiRus leadership team

Management profile

Number of profiles

Profiles6 records

MiRus funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MiRus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiRus

What does MiRus do?

MiRus designs, manufactures, and commercializes medical implants and procedural solutions for spine, extremity/orthopedic, and structural heart applications, all built on its proprietary MoRe (Molybdenum-47.5 Rhenium) nickel-free superalloy. The integrated platform spans pre-operative planning (e.g., GALILEO), intra-operative implants (pedicle screws, interbody cages, cervical plates, foot/ankle plates, TAVR), and post-operative monitoring. The company sells these products to hospitals and healthcare systems in the United States through an enterprise field sales team and a distributor network.

Is MiRus a public or private company?

MiRus is a private company. It is classified as venture growth investor backed and is currently operating.

When was MiRus founded?

MiRus was founded in 2019. It employs 101 to 250 people.

Where is MiRus based?

MiRus is headquartered in Marietta, United States, in the North America region.

How does MiRus make money?

One revenue line is on record: medical Device Sales (Spine, Orthopedic, Structural Heart).

Who are MiRus's main competitors?

Direct peers on record are Edwards Lifesciences, Orthofix Medical, Alphatec Holdings, Globus Medical, SeaSpine (now Globus Medical) and Wright Medical (Stryker Trauma & Extremities). Broad incumbents are Medtronic, Stryker and Boston Scientific. 4WEB Medical is listed as an emerging player.

Does MiRus have an API?

No public API is recorded for MiRus.

What industry is MiRus in?

MiRus's product category is Orthopedic and Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation), with a secondary code of HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsHow MiRus got $1.5B Boston Scientific investment for heart valveMiRus, a firm based in Marietta, is pursuing FDA approval for a heart valve replacement, supported by a $1.5 billion investment from Boston Scientific. This investment aims to facilitate the development of the heart valve using a superalloy. The founder, Dr. Jay Yadav, has a personal motivation for this project.American City Business JournalsHow MiRus got $1.5B Boston Scientific investment for heart valveMiRus, a Marietta-based firm, is pursuing FDA approval for a heart valve replacement using a superalloy. The company received a $1.5B investment from Boston Scientific, and founder Dr. Jay Yadav's expansion is driven by this backing and the death of a mentor.PitchBookQ2 2026 Medtech Report: MiRus Lifts VC Funding in Q2Q2 2026 medtech venture capital funding climbed to $4.9 billion from $3.7 billion in Q1, driven primarily by Boston Scientific's $1.5 billion later-stage investment in MiRus, a molybdenum-rhenium implant developer, at a $4.4 billion post-money valuation representing roughly 34% strategic stake. Despite the funding surge, deal counts declined for a second consecutive quarter, with surgical devices and tools accounting for approximately $3 billion across 78 deals, while VC exits remained strong at $4.3 billion for a fourth consecutive quarter.AijournBoston Scientific announces results for second quarter 2026Boston Scientific Corporation reported second quarter 2026 net sales of $5.442 billion, representing 7.5% growth year-over-year on a reported basis, with GAAP EPS of $0.61 and adjusted EPS of $0.86, exceeding the guidance range of $0.82 to $0.84 per share. The company completed a $2 billion accelerated share repurchase program and invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business, while also receiving FDA 510(k) clearance for the TruSelect 2.6 Microcatheter. Looking ahead, Boston Scientific raised full-year guidance to net sales growth of 5.5% to 6.5% on a reported basis and adjusted EPS of $3.28 to $3.32.Stock TitanBoston Scientific Q2 Earnings: $5.442B SalesBoston Scientific Corporation reported Q2 2026 net sales of $5.442 billion, representing 7.5% growth on a reported basis and 7.0% on an operational and organic basis, compared to the prior year period. The company achieved GAAP EPS of $0.61 and adjusted EPS of $0.86, exceeding its guidance range of $0.82 to $0.84 per share, while completing a $2 billion accelerated share repurchase program. Boston Scientific also invested $1.5 billion in MiRus LLC for an approximately 34% equity stake with an exclusive option to acquire the company's TAVR business, and received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter.BioSpaceBoston Scientific announces results for second quarter 2026Boston Scientific reported Q2 2026 net sales of $5.442 billion, up 7.5% year-over-year, and GAAP EPS of $0.61. The company also announced forward guidance for full-year 2026 net sales growth of 5.5-6.5% and adjusted EPS of $3.28-$3.32.PR NewswireBoston Scientific announces results for second quarter 2026Boston Scientific reported Q2 2026 net sales of $5.442 billion, up 7.5% year-over-year, and GAAP EPS of $0.61. The company also announced forward guidance for full-year 2026 net sales growth of 5.5-6.5% and adjusted EPS of $3.28-$3.32.YahooTop 10 medtech deals in the first half of 2026Medtech dealmakers remained active in the first half of 2026, with PwC reporting $36.5 billion in medtech acquisitions and deal volumes tracking above the midpoint of 2025, reflecting efforts to refocus portfolios on faster-growing products. Boston Scientific led activity by inking a deal to acquire Penumbra for $14.5 billion and purchasing a stake in MiRus for $1.5 billion. Danaher also entered the list by completing its $9.9 billion acquisition of Masimo, positioning itself as a competitor to Medtronic in the pulse oximetry market.YahooBoston Scientific (BSX) Invests $1.5B in MiRus for Equity Stake and TAVR Acquisition OptionBoston Scientific invested $1.5 billion for a 34% equity stake in MiRus LLC and secured an exclusive option to acquire its proprietary TAVR system for up to $3 billion upon meeting specific clinical and regulatory milestones. The SIEGEL TAVR system, currently undergoing pivotal trials, utilizes a nickel-free rhenium alloy and a smaller delivery sheath designed to reduce vascular injury risks.